Method for inhibiting "melanoma inhibitory activity" mia

Abstract

The present invention is directed to peptides, antibodies and antibody fragments inhibiting activity of “Melanoma Inhibitory Activity” (MIA).

1 . A peptide inhibiting activity of “Melanoma Inhibitory Activity” (MIA) selected from the group consisting of peptides with the sequence SEQ ID No. 1 to 57.  
     
     
         2 . The peptide of  claim 1  wherein one amino acid is substituted by a natural amino acid.  
     
     
         3 . The peptide of  claim 1 , wherein one or more amino acids are substituted by a non-natural amino acid.  
     
     
         4 . The peptide of  claim 3 , wherein the non-natural amino acid is a modified natural amino acid, the modification is a substitution of one or more atoms with a functional group comprising 1 to 12 atoms selected from C, H, N, S, O, P, F, Cl, Br, I, Se.  
     
     
         5 . The peptide of  claim 1  comprising one additional amino acid.  
     
     
         6 . The peptide of  claim 1  wherein one amino acid is deleted.  
     
     
         7 . The peptide of  claim 1  comprising one or more modifications 
 a) selected from the group consisting of glycosylation, acetylation, hydroxylation (hydroxyproline), carboxylation (gamma-carboxyglutamate), phosphorylation, alkylation, myristoylation (N-terminal), palmitoylation and prenylation;    b) as well as non-naturally occurring amino acids including, trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methylglycine, allothreonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4 azaphenylalanine, and 4-fluorophenylalanine.    
     
     
         8 . A medicament comprising at least one peptide according to  claim 1 .  
     
     
         9 . A medicament comprising an antibody or an antibody fragment binding to MIA, especially antibodies against alpha 4 and/or alpha 5-integrins.  
     
     
         10 . The medicament of  claim 9 , wherein the antibody is selected from the group consisting of 
 ANTIBODY NO. 1: anti-alpha 4-integrin (A4-PUJ1, UBI)    ANTIBODY NO. 2: anti-alpha 4-integrin (P1H4, Chemicon)    ANTIBODY NO. 3: anti-alpha 5-integrin (A5-PUJ5, UBI)    ANTIBODY NO. 4: anti-alpha 5-integrin (P1D6, Chemicon)    
     
     
         11 . The medicament according to  claim 8 , further comprising at least one immunostimulatory, chemotherapeutic, gene-therapeutic, anti-angiogenic, anti-invasive and/or vaccine agent.  
     
     
         12 . Use of the medicament according to  claim 8  for the prevention or the treatment of diseases selected from the group consisting of solid tumors (including melanoma and other MIA-overexpressing tumors), leukemia, degenerative disorders, immunosuppressive diseases.  
     
     
         13 . Use of the peptides according to claim for the inhibition of MIA.  
     
     
         14 . Use of an antibody or an antibody fragment directed against alpha 4- and/or alpha 5-integrins for the inhibition of MIA.  
     
     
         15 . Use of the peptides according to  claim 1  for the stimulation and/or induction of precursor cells.  
     
     
         16 . Use of an antibody or an antibody fragment directed against alpha 4- and/or alpha 5-integrins for the stimulation and/or induction of precursor cells.